Proposed site-, timing-, and response-based risk allocation at relapse. Shown is the proposed classification schema for the upcoming COG comprehensive therapeutic trial for children, adolescents, and young adults with relapsed ALL (J. Whitlock, P. Brown, written communication, May 7, 2012). NA indicates novel agent; TP, time point; and IEM, isolated extramedullary.